All-cause and diabetes-related healthcare costs among US adults with type 2 diabetes initiating exenatide once weekly or insulin glargine
Author:
Affiliation:
1. AstraZeneca; Wilmington Deleware
2. Truven Health Analytics, An IBM Company; Ann Arbor Michigan
Funder
AstraZeneca
Publisher
Wiley
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13145/fullpdf
Reference32 articles.
1. American Diabetes Association 2016 http://www.diabetes.org/diabetes-basics/statistics/
2. 8. Pharmacologic approaches to glycemic treatment;American Diabetes Association;Diabetes Care,2017
3. Outcomes and healthcare resource utilization associated with medically attended hypoglycaemia in older patients with type 2 diabetes initiating basal insulin in a US managed care setting;Escalada;Curr Med Res Opin,2016
4. Insulin in America: a right or a privilege?;Hirsch;Diabetes Spectr,2016
5. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability;Garber;Diabetes Care,2011
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Racial Disparities in Health Care With Timing to Amputation Following Diabetic Foot Ulcer;Diabetes Care;2022-09-19
2. Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review;Cardiovascular Diabetology;2021-01-19
3. Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk;Scientific Reports;2021-01-14
4. Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study;BMJ Open Diabetes Research & Care;2019-12
5. Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin;Metabolism;2019-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3